Biodesix Reports 10% Revenue Growth in Q3 2026 Amid Sales Turnover Challenges
Biodesix (BDSX) reported third-quarter revenue of $24.0 million, a 10% increase year-over-year driven primarily by a 16% rise in diagnostic testing revenue. Total test volumes reached 19,400, marking the second-highest quarterly volume in company history. Despite this growth, the company faced headwinds from higher-than-expected sales representative turnover in primary care territories and seasonal fluctuations in physician ordering patterns. The company's net loss improved by 8% to $8.0 million as revenue growth outpaced expense increases. While gross margins remained stable at 81%, they were partially offset by rising shipping costs due to fuel prices. Biodesix has revised its full-year revenue guidance to a range of $101 million to $103 million, citing the timing of sales team expansion and delays in development services projects.
Tickers: $BDSX
Topics: diagnostic testing financial guidance net loss improvement revenue growth
Read the full article at Motley Fool
Part of the story Biodesix Reports 10% Revenue Growth in Q3 2026 Amid Sales Turnover Challenges (2 articles)